The effect of preoperative oral immunonutrition on complications and length of hospital stay after elective surgery for pancreatic cancer: a randomized controlled trial

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

The effect of preoperative oral immunonutrition on complications and length of hospital stay after elective surgery for pancreatic cancer : a randomized controlled trial. / Gade, Josephine; Levring, Trine; Hillingsø, Jens Georg; Hansen, Carsten Palnæs; Andersen, Jens Rikardt.

In: Nutrition and Cancer, Vol. 68, No. 2, 2016, p. 255-233.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Gade, J, Levring, T, Hillingsø, JG, Hansen, CP & Andersen, JR 2016, 'The effect of preoperative oral immunonutrition on complications and length of hospital stay after elective surgery for pancreatic cancer: a randomized controlled trial', Nutrition and Cancer, vol. 68, no. 2, pp. 255-233. https://doi.org/10.1080/01635581.2016.1142586

APA

Gade, J., Levring, T., Hillingsø, J. G., Hansen, C. P., & Andersen, J. R. (2016). The effect of preoperative oral immunonutrition on complications and length of hospital stay after elective surgery for pancreatic cancer: a randomized controlled trial. Nutrition and Cancer, 68(2), 255-233. https://doi.org/10.1080/01635581.2016.1142586

Vancouver

Gade J, Levring T, Hillingsø JG, Hansen CP, Andersen JR. The effect of preoperative oral immunonutrition on complications and length of hospital stay after elective surgery for pancreatic cancer: a randomized controlled trial. Nutrition and Cancer. 2016;68(2):255-233. https://doi.org/10.1080/01635581.2016.1142586

Author

Gade, Josephine ; Levring, Trine ; Hillingsø, Jens Georg ; Hansen, Carsten Palnæs ; Andersen, Jens Rikardt. / The effect of preoperative oral immunonutrition on complications and length of hospital stay after elective surgery for pancreatic cancer : a randomized controlled trial. In: Nutrition and Cancer. 2016 ; Vol. 68, No. 2. pp. 255-233.

Bibtex

@article{5dc26b1059ed4dbe97d446c842c45a72,
title = "The effect of preoperative oral immunonutrition on complications and length of hospital stay after elective surgery for pancreatic cancer: a randomized controlled trial",
abstract = "Major gastrointestinal surgery is associated with immune suppression and a high risk of postoperative complications. The aim of this open, randomized controlled trial was to examine the effect of supplementary per oral immunonutrition (IN) seven days before surgery for pancreatic cancer (PC) on postoperative complications and length of hospital stay (LOS). Secondary outcomes were the changes in functional capability and body weight (BW). Consecutive patients referred for surgery for diagnosed or plausible PC were included. The patients in the intervention group received supplementary IN (Oral Impact{\circledR}, Nestl{\'e}) to reach a goal of 1.5 g protein/kg BW. The control group continued their habitual diet. Complications and LOS were independently assessed by the surgical staff. Secondary outcomes were measured 10, 20, and 30 days postoperatively. Thirty-five patients were included, of whom 19 (54{\%}) were allocated to the intervention group. The doses of IN ranged from 250 to 1000 ml per day and the median compliance was 100 (0-100{\%}). Based on the principle of intention-to-treat, no significant differences were found between the groups. We conclude that the lack of effect could be due to the limited dosage of IN, and/or because only 40{\%} of the patients were at nutritional risk.",
author = "Josephine Gade and Trine Levring and Hillings{\o}, {Jens Georg} and Hansen, {Carsten Paln{\ae}s} and Andersen, {Jens Rikardt}",
note = "CURIS 2016 NEXS 081",
year = "2016",
doi = "10.1080/01635581.2016.1142586",
language = "English",
volume = "68",
pages = "255--233",
journal = "Nutrition and Cancer",
issn = "0163-5581",
publisher = "Taylor & Francis",
number = "2",

}

RIS

TY - JOUR

T1 - The effect of preoperative oral immunonutrition on complications and length of hospital stay after elective surgery for pancreatic cancer

T2 - a randomized controlled trial

AU - Gade, Josephine

AU - Levring, Trine

AU - Hillingsø, Jens Georg

AU - Hansen, Carsten Palnæs

AU - Andersen, Jens Rikardt

N1 - CURIS 2016 NEXS 081

PY - 2016

Y1 - 2016

N2 - Major gastrointestinal surgery is associated with immune suppression and a high risk of postoperative complications. The aim of this open, randomized controlled trial was to examine the effect of supplementary per oral immunonutrition (IN) seven days before surgery for pancreatic cancer (PC) on postoperative complications and length of hospital stay (LOS). Secondary outcomes were the changes in functional capability and body weight (BW). Consecutive patients referred for surgery for diagnosed or plausible PC were included. The patients in the intervention group received supplementary IN (Oral Impact®, Nestlé) to reach a goal of 1.5 g protein/kg BW. The control group continued their habitual diet. Complications and LOS were independently assessed by the surgical staff. Secondary outcomes were measured 10, 20, and 30 days postoperatively. Thirty-five patients were included, of whom 19 (54%) were allocated to the intervention group. The doses of IN ranged from 250 to 1000 ml per day and the median compliance was 100 (0-100%). Based on the principle of intention-to-treat, no significant differences were found between the groups. We conclude that the lack of effect could be due to the limited dosage of IN, and/or because only 40% of the patients were at nutritional risk.

AB - Major gastrointestinal surgery is associated with immune suppression and a high risk of postoperative complications. The aim of this open, randomized controlled trial was to examine the effect of supplementary per oral immunonutrition (IN) seven days before surgery for pancreatic cancer (PC) on postoperative complications and length of hospital stay (LOS). Secondary outcomes were the changes in functional capability and body weight (BW). Consecutive patients referred for surgery for diagnosed or plausible PC were included. The patients in the intervention group received supplementary IN (Oral Impact®, Nestlé) to reach a goal of 1.5 g protein/kg BW. The control group continued their habitual diet. Complications and LOS were independently assessed by the surgical staff. Secondary outcomes were measured 10, 20, and 30 days postoperatively. Thirty-five patients were included, of whom 19 (54%) were allocated to the intervention group. The doses of IN ranged from 250 to 1000 ml per day and the median compliance was 100 (0-100%). Based on the principle of intention-to-treat, no significant differences were found between the groups. We conclude that the lack of effect could be due to the limited dosage of IN, and/or because only 40% of the patients were at nutritional risk.

U2 - 10.1080/01635581.2016.1142586

DO - 10.1080/01635581.2016.1142586

M3 - Journal article

C2 - 26943500

VL - 68

SP - 255

EP - 233

JO - Nutrition and Cancer

JF - Nutrition and Cancer

SN - 0163-5581

IS - 2

ER -

ID: 157433938